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Background. Human noroviruses are the leading cause of acute viral gastroenteritis, justifying vaccine develop-
ment despite a limited understanding of strain immunity. After genogroup I (GI).1 norovirus infection and immu-
nization, blockade antibody titers to multiple virus-like particles (VLPs) increase, suggesting that GI cross-protection
may occur.
Methods. Immunoglobulin (Ig)Awas puriﬁed from sera collected from GI.1-infected participants, and potential
neutralization activity was measured using a surrogate neutralization assay based on antibody blockade of ligand
binding. Human and mouse monoclonal antibodies (mAbs) were produced to multiple GI VLPs to characterize
GI epitopes.
Results. Immunoglobulin A puriﬁed from day 14 post-GI.1 challenge sera blocked binding of GI.1, GI.3, and
GI.4 to carbohydrate ligands. In some subjects, puriﬁed IgA preferentially blocked binding of other GI VLPs
compared with GI.1, supporting observations that the immune response to GI.1 infection may be inﬂuenced by
pre-exposure history. For other subjects, IgA equivalently blocked multiple GI VLPs. Only strain-speciﬁc mAbs rec-
ognized blockade epitopes, whereas strain cross-reactive mAbs recognized nonblockade epitopes.
Conclusions. These studies are the ﬁrst to describe a functional role for serum IgA in norovirus immunity and
the ﬁrst to characterize human monoclonal antibodies to GI strains, expanding our understanding of norovirus
immunobiology.
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Noroviruses (NoVs) are a leading cause of gastroenteritis
outbreaks in all age groups, contributing to an estimated
21 million illnesses per year in the United States [1].
Although genogroup II (GII).4 NoV strains predominate
worldwide, a large number of diverse NoV strains cocir-
culate at endemic levels. Genogroup I (GI) strain infec-
tions occur most frequently in children and the elderly
[2, 3].Norovirus disease is usually self-limiting in healthy
individuals, but it can be severe in the very young, elder-
ly, and immunocompromised [3–5]. A NoV vaccine
would beneﬁt these vulnerable groups as well as the mil-
itary, food-handlers, and support-care workers.
An understanding of the complex antigenic relation-
ship between NoV strains will aid in vaccine develop-
ment. Currently, a multivalent (GI.1/GII.4C) virus-like
particle (VLP) vaccine is in phase I clinical trials [6].
Cross-strain reactive blockade Ab responses, a potential
measure of strain cross-neutralization and a correlate to
protective immunity in GI.1-challenged participants [7],
were identiﬁed in serum samples collected during an
initial reactogenicity trial of the vaccine [8]. These
data support the hypothesis that some similar neutral-
izing antibody (Ab) epitopes might exist within both GI
and GII NoV strains that could potentially provide
targets for a broadly protective vaccine.
Likewise, we have previously characterized Ab respons-
es in humans after GI.1 NoV experimental infection [9],
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and we found that GI.1 infection induced blockade Ab cross-
reactive within a panel of GI VLPs. In this follow-up study
using the same serum samples, we extend these observations to
identify serum immunoglobulin (Ig)A as a component of the
cross-GI blockade Ab response, and we characterize the antigenic
relationship between GI VLPs using a panel of monoclonal Abs
(mAbs). These mAbs include the ﬁrst reported human mAbs to
GI NoV strains.
MATERIALS AND METHODS
Ethics Statement
Serum samples were collected from participants infected with
GI.1–1968 in an unpublished pilot study. Participants provided
written informed consent, the original study was approved by
the Institutional Review Board, and the guidelines for human ex-
perimentation were followed in the conduct of clinical research [9].
Human Serum Samples and Genogroup I Virus-Like Particles
The archived, deidentiﬁed serum samples collected from GI.1-
infected participants and GI VLPs used in these studies are
described in refs. [9, 10]. Not all archival samples were available
for analyses. Any missing samples are noted in the respective
ﬁgure legends.
Enzyme Immunoassay, Blockade Antibody, and Blocking of
Binding Assays
Enzyme immunoassay (EIA) and blockade Ab assays were per-
formed as described for GI VLPs [8]with the following exceptions
for the blockade assay: (1) 0.5 µg/mL VLP was used, and (2) the
VLP-serum and VLP-porcine gastric mucin binding steps were
incubated at 37°C. Blocking of binding (BOB) assay procedures
[11] are the same as EIA procedures except that serial dilutions
of mouse mAbs were added to GI.1-coated plates before the ad-
dition of anti-GI.1 human mAbs at a concentration equal to the
EC50 titer (effective concentration at 50%) [8, 11]. All sera and
mAbs were assayed in duplicate in a minimum of at least 2 in-
dependent assays for each VLP.
Avidity Index Calculation
Avidity indexes were determined as described for IgG and IgA
EIA as described in ref. [8], with the inclusion of a 10-minute, 7
Figure 1. Genogroup I (GI).1 infection induces high-titer, high-avidity homotypic serum immunoglobulin (Ig)A and IgG. Serum samples were assayed for
IgA and IgG reactivity to GI.1 by enzyme immunoassay (EIA) and avidity assays. Each color of circle represents the mean EC50 for a participant. The group
geometric mean titer (line) and 95% conﬁdence intervals (error bars) for each timepoint are also reported. Samples with titers or avidities below the limit of
detection (dashed line) were assigned values of 15 for the EIA assay or 10 for the avidity assay for statistical analysis. *Signiﬁcantly different from day O
(Wilcoxon). ^IgA signiﬁcantly different from IgG at the same timepoint (Wilcoxon). #Day 14 signiﬁcantly different from day 35 (Wilcoxon). Three samples
were not available for analysis, 1 each on day 0 (gray), day 4 (yellow), and day 35 (pink). The seroresponse rate is equal to (# Samples Tested/# Matched
with day 0).
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M urea incubation step after the ﬁrst wash postprimary Ab in-
cubation [12]. The index was deﬁned as the average ratio of op-
tical density (OD) of Ab bound in the presence of 7 M urea
compared with the average OD of Ab bound in the absence
of urea at the dilution closest to the Ab EC50. Samples with
Ab levels below the limit of detection were assigned an index
of 10 for statistical purposes. All sera and mAbs were assayed
in duplicate in a minimum of at least 2 independent assays
for each VLP.
Immunoglobulin A Puriﬁcation
Immunoglobulin A was puriﬁed from serum samples using
Peptide M/Agarose (InvivoGen) following the manufacturer’s
directions, except samples were diluted 6-fold in phosphate-
buffered saline before ﬁltration instead of being dialyzed. Puri-
ﬁed IgA samples were conﬁrmed as IgG negative by EIA.
Monoclonal Antibody Production and Puriﬁcation
Mouse mAbs to GI.1 and GI.4 and human mAbs reactive to GI
VLPs were isolated, produced, and puriﬁed as reported previ-
ously [13, 14].
Statistical Analysis
Statistical analyses were done using GraphPad Prism 6.02. EC50
values or geometric mean titers (GMTs) between days postchal-
lenge, or VLPs were compared using the one-way analysis of
variance (ANOVA) with Dunnett posttest (ANOVA), when at
least 3 values were compared or a Wilcoxon test (Wilcoxon)
when only 2 values were compared. A difference was considered
signiﬁcant if the P value was < .05.
RESULTS
Genogroup I .1 Infection Induces Homotypic Immunoglobulin A
and Immunoglobulin G With High Titer and Increased Avidity
Genogroup I.1 infection results in signiﬁcant rises in serum IgG
titer to GI.1 at day 14 postchallenge [9]. To further characterize
this serum response, we compared GI.1-reactive IgA and IgG
titers and avidities at days 0, 4, 14, and 35. Avidity was measured
as an indicator of the degree of strain-speciﬁc somatic hypermu-
tation. Immunoglobulin A GMTs at day 0 and day 4 were below
the assay limit of detection. Immunoglobulin A titers peaked at
day 14 and were signiﬁcantly lower at day 35 (Figure 1A) (Wil-
coxon, P = .004). Immunoglobulin A avidity GMTs were corre-
sponding low (<30%) at day 0 and day 4, peaked at day 14
(58%), and remained elevated at day 35 (44%) (Figure 1B). Im-
munoglobulin G GMTs were low at day 0 and 4, peaked at day
14, and remained elevated at day 35 (Figure 1C). Immunoglob-
ulin G avidity GMTs were low at days 0 and 4 (<30%) and high
at days 14 (76%) and 35 (69%) (Figure 1D). Compared with
IgG, IgA titers were 3.2-fold lower at day 35 and avidities
were signiﬁcantly lower at days 14 (Wilcoxon, P = .01) and 35
(Wilcoxon, P = .004), indicating that the GI.1-induced IgA Ab
titers wane more quickly and are less afﬁnity matured compared
with IgG Abs.
Serum Immunoglobulin A Has Cross-Genogroup I Virus-Like
Particle Blockade Activity
The ability of serum to block binding of NoV VLPs to carbohy-
drate ligands is used as a surrogate neutralization assay in the
absence of a validated NoV cell culture system [7, 8]. We have
previously shown that the day 14 sera from G1.1-infected sub-
jects block binding of GI.1, GI.2, GI.3, and GI.4 VLPs to ligand
[9]. To evaluate the role IgA plays in this broadly blocking ac-
tivity, we puriﬁed IgA from day 14 sera and measured the IgA
blockade Ab titer against GI VLPs. Eight participants had IgA
titers high enough to facilitate IgA puriﬁcation. As reported for
unfractionated sera, puriﬁed IgA blocked GI.1, GI.3, and GI.4
(Figure 2). All IgA samples blocked binding of more than 1
GI VLP (Table 1). In 4 of these 8 (50%), IgA blockade potency
was highest for GI.1. Of note, IgA from subject 3 blocked binding
of all 3 GI VLPs similarly. Like unfractionated sera, sera depleted
of IgA retained broad-GI blockade Ab function, supporting a role
for other Ab isotypes, in addition to IgA, in sera blockade activity
(Table 1).
Genogroup I Virus-Like Particles Share Common Antibody
Epitopes
Immunoglobulin A and sera assays suggest that GI strains may
share cross-reactive Ab epitopes, possibly as a result of multiple
infections. Currently, little is known about GI Ab epitopes and
Figure 2. Day 14 immunoglobulin (Ig)A blocks multiple genogroup I (GI)
virus-like particles (VLPS) from binding ligand. Immunoglobulin A was af-
ﬁnity puriﬁed from day 14 serum samples of subjects infected with GI.1
and tested for blockade potential against GI.1, GI.3, and GI.4 VLPs and
mean EC50 titers calculated. Each color of circle represents the mean
EC50 for a participant. The group geometric mean titer (line) and 95% con-
ﬁdence intervals (error bars) for each VLP are also reported. Samples with
titers above the limit of detection (dashed line) were assigned the value of
32 for statistical analysis. Puriﬁed IgA was not recovered from serum from
participant 1 and 7, each of which had GI.1-reactive IgA titers <200 µg/mL.
*Mean EC50 blockade titer is signiﬁcantly different from GI.1 (analysis of
variance).
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no GI blockade epitopes have been reported. Therefore, we iso-
lated a panel of mouse and human mAbs to directly determine
whether GI strains share common epitopes or whether GI.1 in-
fection activates multiple strain-speciﬁc Ab responses as has
been reported for GII.4 strains postvaccination (Table 2) [8].
Two of 5 mouse mAbs to GI.1 were strain-speciﬁc, whereas 3
recognize multiple GI VLPs by EIA (Figure 3A). Contrary to
polyclonal Ab responses post-GI.1 infection, all 5 mAbs prefer-
entially recognize GI.1. None of the mouse GI.1 mAbs block
binding of GI.1 VLP to carbohydrate ligand (Figure 3B). In
comparison, all 4 mouse mAbs to GI.4 were strain-speciﬁc to
GI.4 (Figure 3C) and effectively blocked binding of GI.4 to car-
bohydrate ligand (Figure 3D). These Abs are the ﬁrst reported
mAbs with GI.4 blockade activity.
Norovirus seropositivity approaches 100% in adults, and pre-
exposure history may shape the Ab response to NoV. Therefore,
we prepared GI-reactive mAbs from blood-banked human pe-
ripheral blood mononuclear cells [14] and tested for cross-GI
reactive epitopes. Of the 4 human mAbs tested, 2 reacted with
more than 1 GI VLP, 1 reacted with GI.1, and another reacted
with GI.3 (Figure 4A). Neither of the cross-reactive mAbs
blocked binding of any tested GI VLP to ligand (Figure 4B).
However, the mAbs that only recognized GI.1 or GI.3 both
blocked binding of the VLPs to ligand. These mAbs are the
ﬁrst reported human mAbs to GI strains and demonstrate the
existence of both cross-GI reactive Ab epitopes and strain-
speciﬁc GI blockade epitopes.
Previous studies with GII.4 NoVs have identiﬁed strain-
speciﬁc epitopes on the surface of the viral particle. Using the
paired human and mouse mAbs to GI.1 and an Ab binding
competition assay (BOB assay) [11] allowed us to gage the rel-
ative spatial arrangement of the GI.1 blockade epitope recog-
nized by human mAb NVB 106 to the nonblockade epitopes
recognized by the mouse GI.1 mAbs. None of the mouse GI.1
mAbs were able to block binding of NVB 106 in the BOB assay,
suggesting that the GI.1 blockade epitope is spatially distinct
from the nonblockade epitopes (Figure 5). The GI.1E (mouse
GI cross-reactive mAb) blocked binding of the human GI
Table 1. Genogroup I Virus-Like Particle Blockade by Day 14 Serum Unfractionated, Serum Depleted of IgA and Puriﬁed IgA
Subject VLP Serum EC50
a,b Serum-IgA EC50
a,b Purified IgA EC50
b,c,d
2 GI.1 308.50 (224.20–424.40) 103.40 (74.79–142.90) 7.31 (5.91–9.04)
GI.3 94.72 (68.63–130.700) 40.56 (35.45–46.40) 32.00 (32.00–32.00)
GI.4 2417.00 (2067.00–2827.00) 410.40 (467.90–359.90) 2.53 (2.31–2.78)
3 GI.1 1271.00 (955.00–1691.00) 257.20 (192.20–344.20) 4.46 (3.76–5.30)
GI.3 1404.00 (1202.00–1639.00) 340.10 (302.30–382.60) 4.54 (4.11–5.03)
GI.4 1148.00 (644.60–2043.00) 515.00 (613.60–432.10) 4.40 (4.06–4.77)
4 GI.1 430.50 (318.80–581.50) 71.20 (53.88–94.09) 5.05 (4.12–6.19)
GI.3 193.20 (171.80–217.30) 83.62 (71.08–98.38) 10.01 (8.92–11.31)
GI.4 575.10 (530.80–623.10) 75.49 (62.97–90.51) 8.40 (7.69–9.20)
6 GI.1 845.80 (770.60–928.50) 174.50 (147.10–207.10) 1.86 (1.69–2.05)
GI.3 109.80 (92.68–130.20) 21.60 (16.65–28.03) 1.00 (0.90–1.11)
GI.4 847.60 (688.60–1043.00) 381.90 (334.70–435.70) 6.20 (5.16–7.46)
7 GI.1 662.80 (502.30–874.60) 32.05 (16.01–64.15) 3.20 (2.90–3.54)
GI.3 141.40 (122.50–163.10) 55.43 (47.71–64.40) 4.75 (4.46–5.10)
GI.4 2313.00 (2068.00–2587.00) 315.60 (245.50–405.70) 1.16 (1.05–1.28)
8 GI.1 278.80 (220.40–352.60) 149.90 (111.70–201.20) 3.95 (3.51–4.44)
GI.3 276.20 (225.20–338.70) 79.41 (64.31–98.06) 9.61 (7.90–11.68)
GI.4 302.80 (190.80–480.30) 98.00 (57.19–167.90) 6.81 (5.41–8.57)
9 GI.1 342.50 (263.80–444.90) 134.00 (178.70–100.50) 5.45 (4.79–6.19)
GI.3 270.10 (234.90–310.50) 100.10 (82.32–121.80) 12.03 (10.72–13.50)
GI.4 593.10 (490.70–716.90) 65.85 (34.43–125.90) 8.17 (7.10–9.42)
10 GI.1 3802.00 (3097.00–4668.00) 631.40 (462.80–861.30) 0.48 (0.42–0.54)
GI.3 5334.00 (4428.00–6424.00) 1095.00 (994.3–1206) 0.96 (0.90–1.02)
GI.4 12095.00 (10066.00–14533.00) 5331.00 (4554.00–6241.00) 0.93 (0.79–1.09)
Abbreviations: Ab, antibody; ANOVA, analysis of variance; GI, genogroup I; Ig, immunoglobulin; VLP, virus-like particle.
a Mean blockade Ab EC50 1/serum dilution (95% confidence interval).
b VLP mean EC50 values significantly different from GI.1 mean EC50 values are bolded (ANOVA).
c Mean blockade IgA EC50 µg/mL (95% confidence interval).
d Samples with titers above the limit of detection were assigned the value of 32 for statistical analysis.
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Table 2. Characteristics of Anti-Genogroup I Norovirus Monoclonal Antibodies
mAb Clone Name Species Isotype Immunogen %Aviditya (VLP) Blockade
GI.1A 68.21.17 Mouse IgG2ak GI.1 50 (GI.1) –
GI.1B 140.6.12 Mouse IgG2ak GI.1 66 (GI.1) –
10 (GI.3) –
GI.1C 140.42.8 Mouse IgM GI.1 62 (GI.1) –
10 (GI.3) –
GI.1D 300.1.28 Mouse IgG2ak GI.1 66 (GI.1) –
41 (GI.3) –
10 (G1.4) –
GI.1E 300.4.2 Mouse IgG2ak GI.1 66 (GI.1) –
GI.4A 4A2.6.4 Mouse IgG2bk GI.4 41 (GI.4) GI.4
GI.4B 4A2.14.13 Mouse IgG2bk GI.4 84 (GI.4) GI.4
GI.4C 4B4.2.7 Mouse IgG2ak GI.4 78 (GI.4) GI.4
GI.4D 8A6.16.11 Mouse IgG2bk GI.4 84 (GI.4) GI.4
NVF 144 144 Human IgG1 Natural Infection 86 (GI.3) GI.3
NVB 106 106 Human IgG1 Natural Infection 98 (GI.1) GI.1
NVB 84 84 Human IgG1 Natural Infection 86 (GI.3) –
72 (GI.4) –
NVE 3 E3 Human IgG1 Natural Infection 100 (GI.1) –
33 (GI.3) –
10 (GI.4) –
Abbreviations: EIA, enzyme immunoassays; GI, genogroup I; Ig, immunoglobulin; mAb, monoclonal antibody; VLP, virus-like particle.
a Avidity was only determined for VLPs with positive EIA results (see Figures 3 and 4).
Figure 3. Reactivity of mouse anti-genogroup I (GI) monoclonal antibodies. Mouse monoclonal antibodies against GI.1 (A and B) or GI.4 virus-like par-
ticles (VLPs) (C and D) were assayed for enzyme immunoassay (EIA) reactivity (A and C) and blockade activity (B and D) for GI.1, GI.3, and GI.4 VLPs, and
mean EC50 titers were determined. Antibodies with EIA or blockade titer above the limit of detection (dashed line) were assigned values of 4 µg/mL or 16
µg/mL, respectively, for statistical analysis. *Mean EC50 signiﬁcantly different from the immunizing strain VLP (analysis of variance).
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cross-reactive mAb (NVE 3), indicating that the mouse mAbs
generated to VLPs recognize relevant epitopes that are targeted
during human infection. Pooled mouse mAbs did not block
binding of NVB 106 and blocked NVE 3 less well than GI.1E
alone, indicating that BOB activity may be related to epitope
distance and frequency and not to steric hindrance from epitope
saturation.
DISCUSSION
Noroviruses are characterized by extensive antigenic diversity
among the GI and GII genotypes. Identiﬁcation of type-speciﬁc
and cross-genotype epitopes will provide epitope-deﬁned diag-
nostic assays that will facilitate development of a broadly protec-
tive NoV vaccine and an immune therapeutic. To begin to
understand the origins of cross-reactive Ab responses, we ana-
lyzed IgA and IgG serum titers and avidities in samples that
present cross-reactive GI Abs at day 14 post-GI.1 infection
[9]. The GI.1-speciﬁc IgG and IgA titers and avidities remained
consistent at day 4 postchallenge and peaked at day 14. Com-
pared with IgG, IgA titer and avidity waned more quickly,
possibly reﬂecting the homing of IgA Ab-secreting cells from
the peripheral blood to mucosal sites [15]. Prechallenge IgG
and IgA titers with avidities above 40% were detected in 2
of the 10 (20%) participants who became infected with GI.1.
Furthermore, high avidity was not predictive of blockade func-
tion among mAbs. Although the design of this study does not
allow prediction of correlates of protective immunity, together,
these data suggest that the location of Ab binding may be more
important in determining protection from infection than Ab
titer or avidity.
A functional role for serum IgG in NoV immunity has been
established by demonstrating that human IgG mAbs have
blockade activity [14, 16] and that IgG memory B-cell titers cor-
relate with protection from GI.1 infection [17]. Mucosal IgA ti-
ters, as measured in saliva, have also been shown to correlate
with protection from GI.1 infection [17, 18]. These studies are
the ﬁrst to assess the blockade activity of IgA. To distinguish
IgA blockade potency from IgG, IgA was puriﬁed from the
day 14 serum samples with total GI.1-reactive IgA titer greater
than 200 µg/mL. All 8 IgA preparations had cross-GI blockade
activity, identifying IgA as a component of the serological
blockade Ab response to GI NoVs. Supporting studies with
polymeric monoclonal IgA indicating that IgA is strain cross-
reactive [19], puriﬁed IgA did not preferentially block ligand
binding of GI.1 compared with other GI VLPs. The IgA re-
sponse may have been generated to cross-reactive epitopes in
response to either the current GI.1 infection or an earlier GI ex-
posure. Supporting this hypothesis, serum and serum depleted
of IgA frommultiple participants, and IgA from one participant
blocked the 3 GI VLPs equivalently, indicating that conserved
GI blockade epitopes exist or that infection with 1 strain elicits
Figure 5. Genogroup (GI).1 blockade epitope is structurally distinct from
GI.1 nonblockade epitopes. Mouse monoclonal antibodies (mAbs) to GI.1
nonblockade epitopes (mAbs GI.1A, B, D, E) were measured for ability to
block GI.1 virus-like particle binding of human mAbs to a strain-speciﬁc
blockade epitope (black circle, NVB106) or a conserved nonblockade epi-
tope (gray circle, NVE 3) in an epitope-speciﬁc blocking-of-binding (BOB)
assay. Mouse antibodies unable to block human antibody binding at titers
within the limit of detection (dashed line) were assigned values of 16 µg/
mL for statistical analysis. *Mean BOB EC50 titer signiﬁcantly different
from GI.1E for the same human antibody (Wilcoxon). Pool: 2 µg/mL each
GI.1A, B, D, and E.
Figure 4. Reactivity of human anti-genogroup I (GI) monoclonal antibod-
ies (Abs). Human monoclonal Abs reactive with GI virus-like particles
(VLPs) were assayed for enzyme immunoassay (EIA) reactivity (A) and
blockade activity (B) for GI.1, GI.3, and GI.4 VLPs, and mean EC50 titers
were determined. Antibodies with EIA or blockade titer above the limit
of detection (dashed line) were assigned values of 4 µg/mL or 16 µg/mL,
respectively, for statistical analysis. *Mean EC50 titer signiﬁcantly different
from GI.3 titer (analysis of variance).
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pre-exposure memory responses against other closely related GI
strains. More importantly, this ﬁnding was observed using an-
tigen-limiting conditions, designed to emphasize strain anti-
genic differences, as opposed to our previous analysis of these
samples in which assays were optimized for sensitivity resulting
in no group difference in serum IgG or blockade Ab titers
between GI VLPs [8, 9]. To clearly deﬁne Ab epitopes, large
panels of human mAb are needed. The data presented here sug-
gest that clone selection processes should include IgA as well as
IgG isotypes.
Mouse mAbs to GI VLPs have been described by others [20,
21], but none have identiﬁed GI blockade Ab potency or epi-
topes, contrary to GII.4 NoVs [14, 22]. Therefore, we developed
a panel of GI mAbs to evaluate the antigenic relationship be-
tween GI VLPs. Unlike GI.1 infection in humans, GI.1 or
GI.4 immunization of mice resulted in Abs that preferentially
recognize the immunizing strain, again suggesting that pre-ex-
posure history may shape the GI Ab response in humans. Six of
the GI Abs appear to have type-speciﬁc blockade activity against
the panel of GI VLPs tested because all recognized only 1 GI
VLP. However, we cannot deﬁnitively infer from these data
that blockade epitopes are strain-speciﬁc, because representa-
tives of each of the GI genotypes were not tested. The remaining
7 mAbs recognized nonblockade epitopes. In particular, none
of the 5 mouse GI.1 mAbs had blockade activity. Although
atypical in our experience with NoV mAbs, it is unlikely that
the lack of blockade potency is related to immunization or hy-
bridoma production protocols because the mouse GI.1 mAbs
were developed simultaneously with the mouse GI.4 mAbs
and all of the GI.4 mAbs recognize a blockade epitope. Anti-
bodies can confer protection from infection by additional
means besides blocking of ligand interaction, including comple-
ment lysis, opsonization, and Ab-dependent cell cytolysis;
therefore, a nonblocking phenotype does not decrease the bio-
logical signiﬁcance of these Abs.
CONCLUSIONS
Most cross-reactive mouse and human GI mAbs had a higher
avidity to a single GI VLP and less avidity to other GI VLPs,
supporting the hypothesis that strain cross-reactive Abs are gen-
erated to sequences in a single strain that are conserved within
other GI VLPs, although to varying degrees of homology. Struc-
tural studies of Ab-bound VLPs and bioinformatics and genetic
tools to create VLPs with altered predicted Ab epitopes com-
bined with a large panel of mAbs may deﬁne GI strain-speciﬁc
and strain cross-reactive epitopes that can be exploited as diag-
nostic tools to measure epitope-speciﬁc responses and to reﬁne
the design of a broadly protective NoV vaccine. Additional
human challenge studies are critical for creating mAb panels,
mapping relevant epitopes, and deﬁning correlates of protective
immunity.
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